Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

W tym Artykule

  • Podsumowanie
  • Streszczenie
  • Wprowadzenie
  • Protokół
  • Wyniki
  • Dyskusje
  • Ujawnienia
  • Podziękowania
  • Materiały
  • Odniesienia
  • Przedruki i uprawnienia

Podsumowanie

The present protocol describes the echocardiographic characterization of right ventricular morphology and function in a rat model of pulmonary arterial hypertension.

Streszczenie

Pulmonary arterial hypertension (PAH) is a progressive disease caused by vasoconstriction and remodeling of the small arteries in the lungs. This remodeling leads to increased pulmonary vascular resistance, worsened right ventricular function, and premature death. Currently approved therapies for PAH largely target pulmonary vasodilator pathways; however, recent emerging therapeutic modalities are focused on other novel pathways involved in the pathogenesis of the disease, including right ventricle (RV) remodeling. Imaging techniques that allow longitudinal assessment of novel therapeutics are very useful for determining the efficacy of new drugs in preclinical studies. Noninvasive trans-thoracic echocardiography remains the standard approach to evaluating heart function and is widely used in rodent models. However, echocardiographic evaluation of the RV can be challenging due to its anatomical position and structure. In addition, standardized guidelines are lacking for echocardiography in preclinical rodent models, making it difficult to carry out a uniform assessment of RV function across studies in different laboratories. In preclinical studies, the monocrotaline (MCT) injury model in rats is widely used to evaluate drug efficacy for treating PAH. This protocol describes the echocardiographic evaluation of the RV in naïve and MCT-induced PAH rats.

Wprowadzenie

PAH is a progressive disease defined as a mean pulmonary arterial pressure at rest of greater than 20 mmHg1. Pathological changes in PAH include pulmonary artery (PA) remodeling, vasoconstriction, inflammation, and fibroblast activation and proliferation. These pathological changes lead to increased pulmonary vascular resistance and, consequently, right ventricular remodeling, hypertrophy, and failure2. PAH is a complex disease that involves crosstalk between several signaling pathways. The currently approved drugs for treating PAH mostly target vasodilator pathways, including the nitric oxide-cyclic guanosine monophosph....

Protokół

All experiments in this protocol were performed following the animal care guidelines of the University of Illinois at Chicago, Chicago Institutional Animal Care and Use Committee. Male Sprague Dawley (SD) rats weighed between 0.200-0.240 kg at the time of MCT injection; however, the protocol described in this article can be used with a wider body weight range. The animals were obtained from a commercial source (see Table of Materials).

1. Study design

  1. Animals
    1. Obtain male SD rats and allow them to acclimate for 4-7 days. Group-house the rats by the experimental group in clean cages an....

Wyniki

In this study, MCT-treated rats were used as a model of PAH. Echocardiographic analysis was performed on Study Day 23 post-MCT administration, and all measurements and calculations represented averages from three consecutive cycles. Echocardiographic parameters obtained from control (vehicle: deionized water) and MCT-treated (60 mg/kg) rats are shown in Table 1.

Representative images of the PLAX view in control and MCT-treated rats are shown in Figure 1A

Dyskusje

Echocardiographic evaluation of the RV is a valuable discovery tool for the screening of the effectiveness of novel treatments in animal models of PAH. In-depth characterization of the RV structure and function is necessary as novel targets in treating PAH address RV remodeling4,14. This study describes a detailed protocol that allows for the successful characterization of RV structure and function.

The complex structural geometry and .......

Ujawnienia

The authors have nothing to disclose.

Podziękowania

This work was supported by NHLBI K01 HL155241 and AHA CDA849387 awarded to the author P.C.R.

....

Materiały

NameCompanyCatalog NumberComments
0.9% sodium cloride injection USPBaxter2B1324
Braided cotton rolls4MD Medical SolutionsRIHD201205
Depilating agentWallgreensNair Hair Remover 
Electrode gelParker Laboratories 15-60
High frequency ultrasound image system and imaging stationFUJIFILM VisualSonics, Inc.Vevo 2100
IsofluraneMedVetRXISO-250
Male sprague Dawley ratsCharles River LaboratoriesCD 001CD IGS Rats (Crl:CD(SD))
Monocrotaline (MCT)Sigma-AldrichC2401
Rectal temperature probe  Physitemp RET-3
Sealed induction chambersScivena ScientificRES644 3 L size
Solid-state array ultrasound transducerFUJIFILM VisualSonics, Inc.Vevo MicroScan transducer MS250S
Stainless steel digital calipersVWR Digital Calipers62379-531
Ultrasound gel Parker Laboratories 11-08
Vevo Lab softwareFUJIFILM VisualSonics, Inc.Verison 5.5.1

Odniesienia

  1. Galie, N., McLaughlin, V. V., Rubin, L. J., Simonneau, G. An overview of the 6th World Symposium on Pulmonary Hypertension. European Respiratory Journal. 53 (1), 1802148 (2019).
  2. Tyagi, S., Batra, V. Novel therapeutic approac....

Przedruki i uprawnienia

Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE

Zapytaj o uprawnienia

Przeglądaj więcej artyków

Echocardiographic AssessmentRight Ventricle FunctionPulmonary Arterial HypertensionRat ModelVentricular MorphologySystolic FunctionDiastolic FunctionMonocrotalineImaging TechniqueElectrode GelElectrocardiogram Lead PlatesTemperature ProbeTransducer PositioningB Mode Imaging

This article has been published

Video Coming Soon

JoVE Logo

Prywatność

Warunki Korzystania

Zasady

Badania

Edukacja

O JoVE

Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone